The clinical trial is sponsored by the Chinese PLA General Hospital and aims to evaluate the safety and efficacy of autologous CD19-targeting STAR-T cell therapy in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL). Given the increasing prevalence of B-NHL and the limitations of existing CAR-T therapies, this innovative approach may provide a competitive edge in the CAR-T market. The trial's focus on a novel mechanism that potentially reduces toxicity while maintaining efficacy could attract interest from investors and pharmaceutical companies looking to expand their oncology portfolios. The estimated patient enrollment of 19 to 38 suggests a targeted approach that may facilitate rapid data collection and analysis, enhancing the asset's attractiveness for future partnerships or acquisitions.